Summarized by Masters of Longevity from Nature Aging.
This article previews a laboratory study examining late-life GLP-1 receptor agonist treatment in mice, inviting readers to learn how researchers compared its aging-related effects with calorie restriction.
Key Takeaways
- Daily semaglutide treatment started at 20 months of age extended median lifespan in female mice compared with vehicle-treated controls.
- Mice received three months of semaglutide for physiological and molecular tests and five months for direct comparison with calorie restriction.
- The study was designed to evaluate late-life GLP-1 receptor activation as a potential calorie restriction mimetic and measured lifespan outcomes accordingly.
